Literature DB >> 30370557

Emerging roles of noncoding RNAs in multiple myeloma: A review.

Qian Yang1,2, Xianjuan Shen3, Zhangyao Su2, Shaoqing Ju1.   

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by unrestricted secretion of monoclonal immunoglobulin and uncontrolled plasma cell proliferation. Extra-medullary infiltration and drug resistance are two major obstacles in the treatment of MM. To solve these problems, it is necessary to elucidate the underlying pathological mechanisms and find new therapeutic targets. Noncoding RNAs (ncRNAs), which were once considered "transcriptional noise," have been recognized as crucial regulators in the process of tumorigenesis including MM. Increasing evidence has shown that ncRNAs participate in MM pathogenesis via a series of complex cellular or extracellular processes. This review article summarizes examples of ncRNAs involved in myelosis and discusses their potential as biomarkers and therapeutic targets in the diagnosis and treatment of myelosis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  exosomes; long noncoding RNAs; mircoRNAs; multiple myeloma; noncoding RNAs

Mesh:

Substances:

Year:  2018        PMID: 30370557     DOI: 10.1002/jcp.27547

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.

Authors:  Yanbei Sun; Tingxiu Jiang; Yongqing Jia; Jingyun Zou; Xiaoxiao Wang; Weiying Gu
Journal:  Cell Cycle       Date:  2019-08-09       Impact factor: 4.534

Review 2.  CircRNAs: novel therapeutic targets in multiple myeloma.

Authors:  Xinyi Zhou; Juan Du
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.316

Review 3.  Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer.

Authors:  Mengwei Wang; Tianwei Xu; Wenyan Feng; Junxia Liu; Zhaoxia Wang
Journal:  Onco Targets Ther       Date:  2021-04-07       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.